GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

What Was Tested

This registered phase 4 trial tested Semaglutide for psoriasis and psoriatic arthritis.

Glucagon-Like Peptide-1 (GLP-1) receptor agonists are cardiovascular protective in diabetics.

They have also anti-inflammatory properties.

It had two arms (groups): semaglutide (experimental) and Control (other).

No active drug administered.

The registry classes the interventions as drug and other.

More on the Plan

Glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonists are a new class of antidiabetic medications.

However, their effects on CV outcomes in patients with non-DM remain uncertain.

On top of being CV protective, the potential anti-inflammatory properties of GLP-1 receptor agonists make them appealing treatment option for patients with inflammatory arthritis.

GLP-1 receptor agonists inhibit lipopolysaccharide-induced inflammation by phosphorylating AMP-activated protein kinase, which leads to the inhibition of the nuclear factor kappa B (NF-κB) pathway.

Who Took Part

40 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Fulfill the ClASsification criteria for Psoriatic Arthritis,. Are rheumatoid factor negative,. BMI \>=25 kg/m2,. Are over 18 years old and.

The full record lists 5 inclusion and 8 exclusion criteria; among the exclusions: have prior therapy with glp-1 receptor agonists during the last 24 weeks,; have pre-existing diabetes,; have liver or renal impairment,.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the psoriasis and psoriatic arthritis participants stayed in one arm throughout.

Nothing was hidden in this open-label Semaglutide study: the psoriasis and psoriatic arthritis participants and staff both knew the treatment.

It started in 2025-12-01 with completion listed for 2027-01-01.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Difference in the proportion of subjects with CIMT between the semaglutide group and control group over a period of 24 weeks (time frame: 24 weeks).

It also tracked 11 secondary outcomes, for example Carotid plaque progression, total plaque area (TPA), BMI, waist circumferences, sugar profile and sugar profile.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 40 people with psoriasis and psoriatic arthritis.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, Psoriasis and psoriatic arthritis research.